Celltrion Pharm Inc
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals a… Read more
Celltrion Pharm Inc (068760) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.055x
Based on the latest financial reports, Celltrion Pharm Inc (068760) has a cash flow conversion efficiency ratio of 0.055x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩23.44 Billion) by net assets (₩426.42 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Celltrion Pharm Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Celltrion Pharm Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Celltrion Pharm Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celltrion Pharm Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mach Natural Resources LP
NYSE:MNR
|
0.054x |
|
Sunshine Insurance Group Company Limited
F:E57
|
N/A |
|
MOLTEN VENTURES LS-01
F:GRW
|
N/A |
|
LOVISA HLDGS DEF.
F:LO7
|
N/A |
|
Jointo Energy Investment Co Ltd Hebei
SHE:000600
|
0.096x |
|
Medikaloka Hermina PT
JK:HEAL
|
0.032x |
|
SENSIRION HOLDING
F:1Q3
|
N/A |
|
Daktronics Inc
NASDAQ:DAKT
|
0.040x |
Annual Cash Flow Conversion Efficiency for Celltrion Pharm Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Celltrion Pharm Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩396.92 Billion | ₩56.59 Billion | 0.143x | +513.25% |
| 2023-12-31 | ₩376.67 Billion | ₩8.76 Billion | 0.023x | +305.01% |
| 2022-12-31 | ₩356.79 Billion | ₩-4.05 Billion | -0.011x | -104.04% |
| 2021-12-31 | ₩331.97 Billion | ₩93.15 Billion | 0.281x | +132.68% |
| 2020-12-31 | ₩300.56 Billion | ₩36.25 Billion | 0.121x | +21.24% |
| 2019-12-31 | ₩280.03 Billion | ₩27.85 Billion | 0.099x | +87.67% |
| 2018-12-31 | ₩270.03 Billion | ₩14.31 Billion | 0.053x | +253.13% |
| 2017-12-31 | ₩293.62 Billion | ₩-10.16 Billion | -0.035x | +21.58% |
| 2016-12-31 | ₩344.65 Billion | ₩-15.21 Billion | -0.044x | -178.02% |
| 2015-12-31 | ₩236.23 Billion | ₩13.36 Billion | 0.057x | -29.99% |
| 2014-12-31 | ₩214.43 Billion | ₩17.33 Billion | 0.081x | -- |